49. Systemic lupus erythematosus Clinical trials / Disease details

Clinical trials : 946 / Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03155477 (ClinicalTrials.gov)	June 10, 2016	13/5/2017	Effect Of Curcuma Xanthorrhiza and Vitamin D3 Supplementation in SLE Patients With Hypovitamin D	Effect Of Curcuma Xanthorrhiza Supplementation In Systemic Lupus Erythematosus Patients (SLE) With Hypovitamin D Which Were Given Vitamin D3 Towards Disease Activity (SLEDAI), Interleukin-6 (IL-6) And Tumor Growth Factor-ß1 (TGF-ß1) Serum	SLE	Dietary Supplement: Cholecalciferol and C. Xanthorrhiza;Dietary Supplement: Cholecalciferol and placebo	Saiful Anwar Hospital	NULL	Completed	18 Years	45 Years	Female	39	N/A	NULL
2	NCT01709474 (ClinicalTrials.gov)	June 2013	16/10/2012	Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus	Vitamin D3 Effects on Immune Function in Pediatric Systemic Lupus Erythematosus (SLE)	Systemic Lupus Erythematosus	Drug: Vitamin D3 6000 IU;Drug: Vitamin D3 400 IU	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence	Terminated	5 Years	20 Years	All	7	Phase 2	United States
3	NCT00710021 (ClinicalTrials.gov)	November 2008	1/7/2008	Vitamin D3 in Systemic Lupus Erythematosus	Effect of Vitamin D3 on the IFN Alpha Signature in Patients With Systemic Lupus Erythematosus (ALE02)	Systemic Lupus Erythematosus;SLE;Lupus	Drug: Vitamin D3;Drug: Vitamin D3 placebo	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence	Completed	18 Years	N/A	All	57	Phase 2	United States